產(chǎn)品詳情
僅用于工業(yè)應(yīng)用或科學研究,不可用于人類或動物的臨床診斷或治療,非藥用. Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia